|
Novel Treatment Strategies for Pancreatic Cancer using Recombinant Acid Sphingomyelinase (2023-072)
Pancreatic Adenocarcinoma (PDAC) is one of the most common cancers worldwide. Despite decade of advancement and research into the multimodal care of PDAC, the outlook remains grim. The majority of patients with PDAC present with metastatic disease at time of diagnosis. Only a minority of patients present with potentially respectable disease and even...
Published: 8/30/2023
|
Updated: 8/30/2023
|
Inventor(s): Gregory Wilson, Erich Gulbins, Syed Ahmad
Keywords(s): Acid Sphingomyelinase, Cancer, Healthcare, Pancreatic Adenocarcinoma (PDAC), Tumor Progression
Category(s): Technology Classifications > Life Sciences, Technology Classifications > Life Sciences > Diseases & Disorders > Cancer, Technology Classifications > Life Sciences > Diseases & Disorders
|
|
Immunotherapeutic Phospholipid for Cancer Treatment (2023-012)
A hallmark feature of malignant cell growth is the presence of an immunosuppressive tumor microenvironment (TME). Cancer cells have evolved mechanisms that promote the escape from the host immune attack which sustains tumor growth. Reversal of immunosuppression in the TME is now considered a powerful approach for cancer treatment.
The TME is a complex...
Published: 8/30/2023
|
Updated: 8/30/2023
|
Inventor(s): Xiaoyang Qi
Keywords(s): Cancer, Healthcare, Immune System, Immunotherapeutic Phospholipid, Tumor Microenvironment (TME)
Category(s): Technology Classifications > Life Sciences > Diseases & Disorders > Cancer, Technology Classifications > Life Sciences, Technology Classifications > Life Sciences > Diseases & Disorders, Technology Classifications > Life Sciences > Diseases & Disorders > Autoimmune, Technology Classifications > Life Sciences > Therapeutics > Biomaterials, Technology Classifications > Life Sciences > Therapeutics
|
|
CXCL-1 Inhibits Natural Killer Cell Cytoxocity
Subtitle
Image*
https://uc.technologypublisher.com/files/sites/image378.png
Description*
Dr. Wise-Draper and her team discovered that CXCL1 is inhibited by metformin in natural killer (NK) cells which in turn results in enhanced NK cellular cytotoxicity. This inhibition of NK cytotoxicity is a new and novel function of CXCL1. NK cells are an...
Published: 8/30/2023
|
Updated: 8/30/2023
|
Inventor(s): McKenzie Crist, Trisha Wise-Draper
Keywords(s): Cancer, CXCL-1 Inhibition, Healthcare, Immune System, Metformin, Natural Killer Cell Cytoxocity
Category(s): Technology Classifications > Life Sciences > Diseases & Disorders > Cancer
|